Institutional Experience With Clofarabine and Cytarabine in Relapsed Pediatric Acute Myeloid Leukemia

被引：3
|
作者：
Moreno, Lucas [1 ]
Maria Fernandez-Navarro, Jose [1 ]
del Mar Andres, Maria [1 ]
Bautista, Francisco [1 ]
Tasso, Maria [2 ]
Verdeguer, Amparo [1 ]
机构：
[1] Hosp Univ Infantil La Fe, Unidad Oncol Pediat, Valencia 46009, Spain
[2] Hosp Gen Univ, Unidad Oncol Pediat, Alicante, Spain
来源：
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY | 2012年 / 34卷 / 01期
关键词：
clofarabine; cytarabine; acute myeloid leukemia; children; GEMTUZUMAB OZOGAMICIN; PHASE-II; CHILDREN; THERAPY; OLDER; 1ST; AML;
D O I：
10.1097/MPH.0b013e31820fee1d
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytarabine (1000 mg/m(2)/d intravenous for 5d) and clofarabine (40 mg/m(2)/d intravenous for 5d) were given every 28 days to 9 children with relapsed acute myeloid leukemia at our institution. Among 19 courses, there were 18 infectious episodes. Median hospitalization time was 13 days (7.7 to 30.5d) per cycle. Hepatobiliary abnormalities included alanine aminotransferase/aspartate aminotransferase elevation and hyperbilirubinemia. Four patients achieved complete remission (one after an earlier allogeneic Haematopoietic Progenitor Cell Transplant). Four patients are alive disease free. In summary, a proportion of children responded and was able to receive allogeneic Haematopoietic Progenitor Cell Transplant. Side effects were tolerable, although hospitalization time was prolonged.
引用
收藏
页码：E17 / E21
页数：5
相关论文
共 50 条
  • [41] A real-world study of clofarabine and cytarabine combination therapy for patients with acute myeloid leukemia
    He, Fiona
    Sapkota, Smarika
    Parker, Sarah
    Defor, Todd
    Warlick, Erica
    Ustun, Celalettin
    Eckfeldt, Craig
    Rashidi, Armin
    Kurtzweil, Andy
    Weisdorf, Daniel
    Bejanyan, Nelli
    LEUKEMIA & LYMPHOMA, 2018, 59 (10) : 2352 - 2359
  • [42] CLOFARABINE AS BRIDGE TO TRANSPLANTATION IN PATIENTS WITH HIGH RISK RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
    Orciuolo, E.
    Buda, G.
    Benedetti, E.
    Caracciolo, F.
    Iovino, L.
    Rousseau, M.
    Galimberti, S.
    Favre, C.
    Petrini, M.
    BONE MARROW TRANSPLANTATION, 2014, 49 : S550 - S550
  • [43] Impact of pharmacokinetics on the toxicity and efficacy of clofarabine in patients with relapsed or refractory acute myeloid leukemia
    Buettner, Bozena
    Knoth, Holger
    Kramer, Michael
    Oertel, Reinhard
    Seeling, Andreas
    Sockel, Katja
    von Bonin, Malte
    Stoelzel, Friedrich
    Alakel, Nael
    Platzbecker, Uwe
    Roellig, Christoph
    Ehninger, Gerhard
    Bornhaeuser, Martin
    Schetelig, Johannes
    Middeke, Jan Moritz
    LEUKEMIA & LYMPHOMA, 2017, 58 (12) : 2865 - 2874
  • [44] CLOFARABINE IN RELAPSED-REFRACTORY ACUTE MYELOGENOUS LEUKEMIA: A SINGLE CENTRE EXPERIENCE
    Scappini, B.
    Gianfaldoni, G.
    Armenio, M.
    Mannelli, F.
    Cutini, I.
    Piccini, M.
    Biagiotti, C.
    Fanci, R.
    Di Gioia, M.
    Bosi, A.
    HAEMATOLOGICA, 2017, 102 : 680 - 680
  • [45] Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia
    Messinger, Yoav
    Boklan, Jessica
    Goldberg, John
    DuBois, Steven G.
    Oesterheld, Javier
    Abla, Oussama
    Martin, Alissa
    Weinstein, Joanna
    Hijiya, Nobuko
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2017, 34 (04) : 187 - 198
  • [46] Efficacy and cost-effectiveness of clofarabine with high-dose cytarabine for treatment of relapsed/refractory acute myeloid leukemia (R/R AML).
    Nunnery, Sara
    Wang, Dorothy
    Tan, Marisela
    Fong, Richard
    Lo, Mimi Ming
    Olin, Rebecca L.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation
    Gill, Harinder
    Yim, Rita
    Pang, Herbert H.
    Lee, Paul
    Chan, Thomas S. Y.
    Hwang, Yu-Yan
    Leung, Garret M. K.
    Ip, Ho-Wan
    Leung, Rock Y. Y.
    Yip, Sze-Fai
    Kho, Bonnie
    Lee, Harold K. K.
    Mak, Vivien
    Chan, Chi-Chung
    Lau, June S. M.
    Lau, Chi-Kuen
    Lin, Shek-Yin
    Wong, Raymond S. M.
    Li, Wa
    Ma, Edmond S. K.
    Li, Jun
    Panagiotou, Gianni
    Sim, Joycelyn P. Y.
    Lie, Albert K. W.
    Kwong, Yok-Lam
    CANCER MEDICINE, 2020, 9 (10): : 3371 - 3382
  • [48] Combination of Cladribine, Cytarabine and Topotecan (CLAT) for Relapsed or Refractory Acute Myeloid Leukemia
    Chen, Xiaomei
    Weng, Jianyu
    Wang, Yulian
    Deng, Chengxin
    Luo, Chengwei
    Liao, Pengjun
    Li, Minming
    Huang, Xin
    Lai, Peilong
    Huang, Lisi
    Cao, Zhi
    Wan, Changchun
    Zhong, Liye
    Wu, Suijing
    Lu, Zesheng
    Zou, Xiaoli
    Du, Xin
    BLOOD, 2015, 126 (23)
  • [49] Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia
    Abboud, Ramzi
    Chendamarai, Ezhilarasi
    Rettig, Michael P.
    Trinkaus, Kathryn M.
    Riedell, Peter A.
    Abboud, Camille N.
    Ghobadi, Armin
    Pusic, Iskra
    Stockerl-Goldstein, Keith
    Schroeder, Mark A.
    Vij, Ravi
    Westervelt, Peter
    DiPersio, John F.
    Uy, Geoffrey L.
    HAEMATOLOGICA, 2020, 105 (08) : E404 - E407
  • [50] A Phase I Study of Lenalidomide and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
    Griffiths, Elizabeth A.
    Brady, William
    Tan, Wei
    Vigil, Carlos E.
    Thompson, James E.
    Ford, Laurie A.
    Dickey, Noelle M.
    Sperrazza, Jill
    Wang, Eunice S.
    Wetzler, Meir
    BLOOD, 2014, 124 (21)
12345